Latest Breaking News On - Andrew kucharchuk - Page 2 : comparemela.com

Baton Rouge, LA, Oct. 15, 2021 (GLOBE NEWSWIRE) — Adhera Therapeutics, Inc. (OTCPK: ATRX) (“Adhera” or the “Company”), a clinical stage biopharmaceutical company, today announces that manufacturing has commenced of MLR-1019 (armesocarb) for use in the Company’s planned Phase 2a clinical trial as a new therapeutic for Parkinson’s disease (PD). Adhera is also pleased to inform shareholders that a new patent has been issued covering MLR-1019 in Korea. Adhera is actively working to initiate a Phase 2a study designed to be a multi-center, double blind, randomized, placebo controlled clinical trial conducted in Eastern Europe to evaluate MLR-1019 as the only PD product under development that will address both movement and non-movement aspects of the disease. To the best of the Company’s knowledge, all existing agents that treat movement disorder, exacerbate non-movement disorder features of PD. Enrollment in the Phase 2 trial is expected to consist of Park

New zealandHong kongSouth africaSouth koreaAndrew kucharchukExchange commissionKorean intellectual property officeMelior pharmaceuticalsEurope unionAdhera therapeutics incBaton rougeAdhera therapeuticsEastern europeChief executive officerEastern europeanInvestigational new drug